• About us
• Contact

Advertisement

Organisation › Details

Roivant (Group)

Roivant is dedicated to transformative innovation in healthcare. Roivant focuses on realizing the full potential of promising biomedical research by developing and commercializing novel therapies across diverse therapeutic areas. We partner with innovative biopharmaceutical companies and academic institutions to ensure that important medicines are rapidly developed and delivered to patients. We advance our drug pipelines through wholly- or majority-owned subsidiary companies, including Axovant (neurology), Myovant (women’s health and endocrine diseases), Dermavant (dermatology), Enzyvant (rare diseases), and Urovant (urology). Roivant also plans to launch new companies operating outside of traditional biopharmaceutical development. Roivant’s long-range mission is to reduce the time and cost of developing and delivering new medicines for patients. *

 

	Start	2017-08-11 existent
	Industry	BIOTECH
	Region	Basel BS
	Country	Switzerland
	Street	8 Viaduktstr.
	City	4051 Basel
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2023-07-10

Advertisement

More documents for Roivant (Group)

• [1] VantAI. (2/13/24). "Press Release: VantAI Enters Collaboration With Bristol Myers Squibb to Accelerate Molecular Glue Drug Discovery Through Artificial Intelligence". New York, NY....
• [2] VantAI. (2/7/24). "Press Release: VantAI Appoints Jae Won Kim as Chief Operating Officer and Chief Financial Officer". New York, NY....
• [3] Roche. (10/23/23). "Press Release: Roche Enters into a Definitive Agreement to Acquire Telavant". Basel....
• [4] VantAI. (4/20/22). "Press Release: VantAI Forms Research Collaboration with Boehringer Ingelheim to Identify Novel Protein Degraders". new York, NY & Ingelheim....
• [5] Affimed N.V.. (3/31/22). "Press Release: Affimed Reports 2021 Financial Results and Highlights Recent Operational Progress". Heidelberg....
• [6] Roivant Sciences GmbH. (2/26/21). "Press Release: Roivant Grows Computational Drug Discovery Engine with Acquisition of Silicon Therapeutics". New York, NY, Boston, MA & Basel....
• [7] Medigene AG. (11/12/20). "Press Release: Medigene Provides Q3 2020 Update". Planegg-Martinsried....
• [8] Medigene AG. (10/19/20). "Press Release: Medigene and Cytovant Enter into Service Agreement for DC Vaccine Manufacturing Process Development". Planegg-Martinsried....
• [9] Roivant Sciences GmbH. (10/31/19). "Press Release: Sumitomo Dainippon Pharma and Roivant Sciences Sign Definitive Agreement for Strategic Alliance". Tokyo, Osaka, London & Basel....
• [10] Roivant Sciences GmbH. (10/9/19). "Press Release: Parexel and Datavant Enter Multi-Year Strategic Partnership to Enable the Connection of Real-World Data Across All Parexel Clinical Trials". Boston, MA & San Francisco, CA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.